# rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

Study · id `cardio:ct-nct05700591` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05700591](<https://clinicaltrials.gov/study/NCT05700591>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05700591

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1552 participants.

## Technical summary

Registry record NCT05700591. Randomized; single masking; primary purpose treatment. Start 2023-01-29 (actual); primary completion 2024-03-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1552 participants (enrolled count; ClinicalTrials.gov record NCT05700591, source copy `cardio:ctgov-nct05700591-2024-07-26`, retrieved 2026-10-26)
- Started: 2023-01-29 (actual) (ClinicalTrials.gov record NCT05700591, source copy `cardio:ctgov-nct05700591-2024-07-26`, retrieved 2026-10-26)
- Primary completion: 2024-03-14 (actual) (ClinicalTrials.gov record NCT05700591, source copy `cardio:ctgov-nct05700591-2024-07-26`, retrieved 2026-10-26)
- Completion: 2024-03-14 (actual) (ClinicalTrials.gov record NCT05700591, source copy `cardio:ctgov-nct05700591-2024-07-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05700591, source copy `cardio:ctgov-nct05700591-2024-07-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05700591-2024-07-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
- Acronym: PROST-2
- Condition: Acute Ischemic Stroke
- Intervention (Drug): rhPro-UK
- Intervention (Drug): rt-PA
- Lead sponsor: Tasly Biopharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial (`cardio:pubmed-39617030`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f26710cbbb14617f1965f2ef8750aca8525114592f421796c9457130600558e0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
